Use Of Triple Therapy In A Cohort Of Patients With COPD Associated Wood Smoke And High Risk : Real Life Study Of Five Cases

Introduction: chronic obstructive pulmonary disease associated with exposure to wood smoke (copd-l) is part of 30% of the etiology of this entity. We know that copd-l has different characteristics compared to the association with tobacco. There is little worldwide experience in the use of bronchodilators and inhaled steroids in patients with this disease. Currently, the high risk of patients with copd-l is the main cause of exacerbations and shortterm cardiovascular outcome is the cause of increased morbidity and mortality. Triple therapy is currently a treatment used in patients with copd-t with excellent clinical and symptomatic benefits. Objective: to describe the effect of triple therapy in a series of 5 cases of patients with copd associated with wood smoke (copd-l) after 1-3-6 months of administration, improving symptoms and benefiting lung function. Methods: prospective, cross-sectional, observational real-life study carried out in the department of pulmonology of a third-level hospital in the city of puebla in the period from january 1, 2024 to august 1, 2024 in patients with symptomatic l-copd under the cat scale despite dual bronchodilator therapy treatment. Results: 100% of patients were female, exposed to wood smoke with an average of 196 hours/year, eosinophil count of 338 cells on average, with cat starting greater than 24 points before treatment and 13 points at the end of treatment at 6 months. Decrease to 50% of the eosinophil count, as well as decrease in dyspnea 1 point on the mmrc scale and 5 points on the borg scale. Conclusion: the cases described offer initial evidence of our medical practice on the benefits of triple therapy in patients with copd associated with firewood. Beclomethasone/formoterol/glycopyrronium have demonstrated good tolerance and safety without presenting adverse effects. These benefits have allowed the patient a better quality of life and a radical decrease in the prevalence of symptoms.